Por favor, use este identificador para citar o enlazar este Item:http://hdl.handle.net/20.500.12105/17863
Título
Targeting Protein Kinases to Enhance the Response to anti-PD-1/PD-L1 Immunotherapy.
Autor(es)
Fecha de publicación
2019-05-09
Idioma
Inglés
Tipo de documento
research article
Resumen
The interaction between programmed cell death protein (PD-1) and its ligand (PD-L1) is one of the main pathways used by some tumors to escape the immune response. In recent years, immunotherapies based on the use of antibodies against PD-1/PD-L1 have been postulated as a great promise for cancer treatment, increasing total survival compared to standard therapy in different tumors. Despite the hopefulness of these results, a significant percentage of patients do not respond to such therapy or will end up evolving toward a progressive disease. Besides their role in PD-L1 expression, altered protein kinases in tumor cells can limit the effectiveness of PD-1/PD-L1 blocking therapies at different levels. In this review, we describe the role of kinases that appear most frequently altered in tumor cells and that can be an impediment for the success of immunotherapies as well as the potential utility of protein kinase inhibitors to enhance the response to such treatments.
Palabras clave
MESH
B7-H1 Antigen | Biomarkers, Tumor | Humans | Immunotherapy | Molecular Targeted Therapy | Programmed Cell Death 1 Receptor | Protein Kinases
DOI
Aparece en las colecciones
Acceso a texto completo